Butyrylcholinesterase and cognitive function.
Butyrylcholinesterase (BuChE) is expressed in brain structures involved in cognition, but the effect of selective BuChE inhibitors on human cognitive function is unknown. We report a patient whose cognitive function deteriorated following a reduction and improved following reinstitution of ethopropazine, a selective BuChE inhibitor. We suggest that, because neurons expressing BuChE may be involved in cognition, there is merit to further evaluation of selective BuChE inhibitors in treating cognitive dysfunction.
Darvesh
S
S
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. sdarvesh@is.dal.ca
MacKnight
C
C
Rockwood
K
K
D000328:Adult; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D002091:Butyrylcholinesterase / Q000502:physiology*; D002746:Chlorpromazine / Q000009:adverse effects* / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000139:chemically induced / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D010640:Phenothiazines / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*
D018680:Cholinergic Antagonists; D010640:Phenothiazines; C084820:profenamine; D002091:Butyrylcholinesterase; D002746:Chlorpromazine